Home » Stocks » STIM

Neuronetics, Inc. (STIM)

Stock Price: $7.69 USD -5.34 (-40.98%)
Updated Aug 3, 2021 1:26 PM EDT - Market open
Market Cap 341.58M
Revenue (ttm) 50.06M
Net Income (ttm) -22.72M
Shares Out 25.15M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $7.69
Previous Close $13.03
Change ($) -5.34
Change (%) -40.98%
Day's Open 10.80
Day's Range 7.21 - 10.95
Day's Volume 3,426,724
52-Week Range 2.86 - 22.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

6 hours ago - GlobeNewsWire

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Futur...

Other stocks mentioned: CCHWF, CMPS, CRLBF, GTBIF, HAVLF, MNMD
1 day ago - InvestorPlace

MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the qu...

5 days ago - GlobeNewsWire

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago - Zacks Investment Research

MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

2 weeks ago - GlobeNewsWire

The redesigned My NeuroStar Resource Center provides user-friendly tools to help practices expand awareness of NeuroStar® Advanced Therapy for Mental Health The redesigned My NeuroStar Resource Center p...

2 weeks ago - GlobeNewsWire

MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

1 month ago - GlobeNewsWire

Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

2 months ago - Zacks Investment Research

The company is experiencing a strong rise in demand.

2 months ago - The Motley Fool

Neuronetics (STIM) delivered earnings and revenue surprises of 6.06% and 6.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

MALVERN, Pa., May 04, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the qu...

2 months ago - GlobeNewsWire

MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the ...

3 months ago - GlobeNewsWire

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the ...

4 months ago - GlobeNewsWire

MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the...

4 months ago - GlobeNewsWire

Neuronetics (STIM) delivered earnings and revenue surprises of 24.00% and 2.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Neuronetics (NASDAQ:STIM) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 53.66% year over year to ($0.19), which beat the estimate of (...

5 months ago - Benzinga

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the ...

5 months ago - GlobeNewsWire

Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

5 months ago - Zacks Investment Research

MALVERN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

5 months ago - GlobeNewsWire

MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

5 months ago - GlobeNewsWire

MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products th...

6 months ago - GlobeNewsWire

MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products th...

6 months ago - GlobeNewsWire

MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

6 months ago - GlobeNewsWire

Neuronetics (STIM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

6 months ago - GlobeNewsWire

Amendment provides Neuronetics with available and flexible funding options through 2022 Amendment provides Neuronetics with available and flexible funding options through 2022

7 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

8 months ago - GlobeNewsWire

Neuronetics makes a device that stimulates the brain, showing efficacy in MDD patients. Despite being in business for nearly two decades, this is a small company and a depressed stock.

8 months ago - Seeking Alpha

TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy's patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients TouchStar theta burst protocol...

8 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

8 months ago - GlobeNewsWire

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Neuronetics (STIM) delivered earnings and revenue surprises of 41.94% and 11.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

9 months ago - GlobeNewsWire

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the q...

9 months ago - GlobeNewsWire

The following originally appeared on CapitalWatch An increasing number of Americans becoming increasingly anxious or depressed or worse. To wit, there were more than 72,000 fatal overdoses in 2019 and m...

Other stocks mentioned: CMPS, MMEDF
9 months ago - Benzinga

MALVERN, Pa., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric dis...

9 months ago - GlobeNewsWire

Participating practices educate patients with depression about non-drug treatment options like NeuroStar Advanced Therapy Participating practices educate patients with depression about non-drug treatmen...

10 months ago - GlobeNewsWire

The market leader in transcranial magnetic stimulation therapy applauds leading NeuroStar® Advanced Therapy provider The market leader in transcranial magnetic stimulation therapy applauds leading Neuro...

10 months ago - GlobeNewsWire

Neuronetics will share clinical data on its NeuroStar® Advanced Therapy treatment, including a bipolar depression pilot study, outcomes registry, and DASH protocol Neuronetics will share clinical data o...

10 months ago - GlobeNewsWire

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

MALVERN, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the...

11 months ago - GlobeNewsWire

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

MALVERN, Pa., July 17, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric d...

1 year ago - GlobeNewsWire

Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

MALVERN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric d...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 26, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the...

1 year ago - GlobeNewsWire

Neuronetics, Inc. (STIM) Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About STIM

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 28, 2018
Stock Exchange
NASDAQ
Ticker Symbol
STIM
Full Company Profile

Financial Performance

In 2020, Neuronetics's revenue was $49.24 million, a decrease of -21.41% compared to the previous year's $62.66 million. Losses were -$27.45 million, -5.48% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Neuronetics stock is "Buy." The 12-month stock price forecast is 21.50, which is an increase of 179.58% from the latest price.

Price Target
$21.50
(179.58% upside)
Analyst Consensus: Buy